OPKO Health Acquires ModeX Therapeutics

OptimizeRx Acquires Medicx Health for $95 million

October 12, 2023

Marketing & Advertising

OptimizeRx Corp. (Nasdaq: OPRX) has signed an agreement to acquire Scottsdale-based Medicx Health (Healthy Offers, Inc.) for $95 million, with certain Medicx managers rolling about $10.5 million into OptimizeRx stock. The acquisition will expand OptimizeRx's omnichannel reach by adding Medicx's patient-focused Micro-Neighborhood Targeting platform and analytics, and is expected to be immediately accretive and to increase consolidated revenue run-rate toward $100 million.

Merck Acquires OncoImmune

November 23, 2020

Biotechnology

Merck will acquire all outstanding shares of clinical-stage biopharmaceutical OncoImmune for $425 million upfront in cash, with additional sales-based and regulatory milestone payments possible. The deal centers on accelerating development of OncoImmune’s CD24Fc for severe and critical COVID-19; non-CD24Fc assets will be spun out into a new company in which Merck will invest $50 million for a minority stake.

Chimerix Acquires Oncoceutics

January 7, 2021

Biotechnology

Chimerix (NASDAQ: CMRX) acquired clinical-stage Oncoceutics, gaining the late-stage oncology candidate ONC201 to expand its oncology pipeline. The deal closed January 7, 2021, for $78 million (half stock, half cash) plus potential milestones and royalties.

Sanofi Acquires Amunix Pharmaceuticals

December 21, 2021

Biotechnology

Sanofi has entered into an agreement to acquire Amunix Pharmaceuticals for an upfront payment of approximately $1.0 billion plus up to $225 million in potential development milestones. The acquisition gives Sanofi Amunix’s Pro‑XTEN/XPAT/XPAC masking technology and a pipeline of conditionally activated T‑cell engagers and cytokine therapies (including lead candidate AMX‑818), expanding Sanofi’s immuno‑oncology capabilities.

Takeda Pharmaceutical Company Limited Acquires Maverick Therapeutics, Inc.

March 9, 2021

Biotechnology

Takeda exercised its option to acquire Maverick Therapeutics, obtaining Maverick's COBRA conditionally active bispecific T‑cell engager platform and lead development candidates (TAK‑186 and TAK‑280). The deal, based on a prior collaboration and equity stake, is structured for up to $525 million in upfront and potential milestone payments and will fold Maverick's R&D team into Takeda's organization.

Shionogi Inc. Acquires Qpex Biopharma, Inc.

June 26, 2023

Pharmaceuticals

Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd., entered into a definitive agreement to acquire San Diego-based clinical-stage antimicrobial developer Qpex Biopharma, Inc. The acquisition (upfront $100 million plus up to $40 million in milestones) brings Qpex's investigational beta-lactamase inhibitor xeruborbactam and expands Shionogi's infectious disease R&D capabilities and pipeline.